Allergenic products advisory committee
FDA's Allergenic Products Advisory Committee will address reclassification of Class IIIA allergenic products at an April 7 meeting. Under the classification system for biologics approved prior to 1972, Class III included products that do not have sufficient data for classification; the agency is eliminating the IIIA category, which allowed products to remain on the market until data is collected. An update on FDA's "critical path" initiative is also scheduled. The meeting will be held at the Holiday Inn in Bethesda, Md. beginning at 8:30 a.m...
You may also be interested in...
Recent and upcoming US FDA advisory committee meetings and a summary of topics covered.
The International Medical Device Regulators Forum, perhaps most notorious for its efforts to standardize audit processes between nations with its Medical Device Single Audit Program, is also focusing on harmonizing device reviews and adverse event codes.
Dr Reddy’s Laboratories has become the third Revlimid ANDA sponsor to settle patent litigation action with Bristol Myers Squibb’s Celgene. However, the Indian company will join Alvogen in not being able to launch before first settler Natco, which has partnered with Teva’s Watson.